Bologna-based Cellply has secured €7.15 million in a funding round led by ENEA Tech e Biomedical, with participation from existing shareholders like CDP Venture Capital. This capital infusion will accelerate the international expansion of their VivaCyte® platform and advance next-generation automated functional testing solutions for ATMP quality control. The company, founded in 2013, aims to reduce the cost and complexity of batch release and potency assays for cell therapies.
Amount: $7.2M
